Clinical trial
Late-Onset Treatment Study Extension Protocol
NCT00455195 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00455195 |
|---|---|
| Title | Late-Onset Treatment Study Extension Protocol |
| Official title | An Open-Label Extension Study of Patients With Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704 |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD-II), Glycogenesis Type II, Acid Maltase Deficiency (AMD) |
| Intervention type | Biological |
| Interventions | alglucosidase alfa |
| Enrollment | 81 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Apr 3, 2007 |
| Last update posted | Mar 7, 2014 |
| Countries | Australia, Canada, France, Netherlands, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: